Europeiska unionen - kroatiska - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - cjepiva - profilaksa influence uzrokovana virusom a (h1n1) v 2009. celvapan mora se koristiti u skladu sa službenim vodstvom.

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

pharmamed mado d.o.o., zagreb - aparat za grijanje tekućina

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

medical intertrade d.o.o. dr. franje tuđmana 3 10431 sveta nedelja -

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

sonimed d.o.o. rozganska 8 10110 zagreb -

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

laboratoire innotech international s.a.s., 22 avenue aristide briand, arcueil, francuska - kalcijev karbonat kolekalciferol - tableta za žvakanje - 500 mg + 400 ij - urbroj: jedna tableta za žvakanje sadrži 500 mg kalcija (u obliku kalcijevog karbonata) i 400 ij kolekalciferola (vitamin d3)

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

laboratoire innotech international s.a.s., 22 avenue aristide briand, arcueil, francuska - neomicinsulfat polimiksin b sulfat nistatin - kapsula za rodnicu, meka - 35 000 iu + 35 000 iu + 100 000 iu - urbroj: jedna kapsula za rodnicu sadrži 35 000 iu neomicin sulfata, 35 000 iu polimiksin b sulfata i 100 000 iu nistatina

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.